Graham Collins, Associate Professor, Haematology and Lymphoma Specialist at Oxford Cancer and Haematology Centre, shared a post on X:
“Interesting topline data released on LOTIS-5. Lonca-T plus ritux versus R-GemOx in R/R DLBCL. Met PFS primary endpoint.
No OS benefit so not sure it will rival StarGlo but interesting results all the same.”
Other articles featuring Prof. Collins on OncoDaily.